


Please type a plus sign (+) inside this box → (+)



PTO/SB08A (08-03)

U. S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2

Application Number	10/633,743
Confirmation Number	5602
Filing Date	8/04/2003
First Named Inventor	Jeffrey Lyle Gray
Group Art Unit	1626
Examiner Name	Rebecca Anderson
Attorney Docket Number	9018M2

U. S. PATENT DOCUMENTS

EXAMINER INITIALS ¹	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
RA	1	US-5,541,161	07/30/1996	Krstenansky et al.	
RA	2	US-4,530,836	07/23/1985	Yanaihara et al.	

FOREIGN PATENT DOCUMENTS


EXAMINER INITIALS ¹	Cite No. ¹	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
RA	3	EP 0 132919 B1	10/29/1986	Amano Pharmaceutical Co., Ltd.		
RA	4	WO 97/40017 A2	10/30/1997	Novo Nor disk A/S		
RA	5	WO 97/40017 A3	10/30/1997	Novo Nor disk A/S		
RA	6	WO 00/42213	07/20/2000	The Research Foundation of State U. of NY		
RA	7	WO 00/53583	09/14/2000	Pharmacia & Upjohn AB		
RA	8	WO 00/71101 A2	11/30/2000	Queen's U. of Kingston		
RA	9	WO 00/71101 A3	11/30/2000	Queen's U. of Kingston		
RA	10	WO 01/16097 A1	03/08/2001	Sugen, Inc.		
RA	11	WO 01/74762 A2	10/11/2001	Phycogen, Inc.		
RA	12	WO 01/74762 A3	10/11/2001	Phycogen, Inc.		
RA	13	WO 02/11722 A1	02/14/2002	Aventis Pharma Deutschland GMBH		
RA	14	WO 03/082263 A1	10/09/2003	Ontogen Corp.		
RA	15	WO 99/11606 A2	03/11/1999	Pharmacia & Upjohn Co.		
RA	16	WO 99/11606 A3	03/11/1999	Pharmacia & Upjohn Co.		
EXAMINER	Rebecca Anderson		DATE CONSIDERED 12/15/03			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → [+]



PTO/SB08B (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

TRADEMARK

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 2 of 2

COMPLETE IF KNOWN

Application Number	10/633,743
Confirmation Number	5602
Filing Date	8/04/2003
First Named Inventor	Jeffrey Lyle Gray
Group Art Unit	1626
Examiner Name	Rebecca Anderson
Attorney Docket Number	9018M2

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RA	17	GALAS M.C. et al., "Structure-activity relationship studies on cholecystokinin: analogues with partial agonist activity", Am. J. Physiol., 1988, Vol. 254 (2 Pt.1), pp. G176-G182.	
RA	18	TAKEDA, Y. et al., "Comparison of CCK-8 Receptors in the Pancreas and Brain of Rats Using CCK-8 Analogues", Japn. J. Pharmacol., 1989, Vol. 49, pp. 471-481.	
RA	19	CASTIGLIONE, R. "Structure-Activity Relationships in Ceruletide-like Peptides", Horm. Recept. Dig. Tract Physiol., Proc. Int. Symp., 1977, Vol. 3, pp. 33-42.	
RA	20	BLASKOVICH, M. et al., "Recent discovery and development of protein tyrosine phosphatase inhibitors", Expert Opinion on Therapeutic Patents, Ashley Publications, GB, 2002, Vol. 12, No. 6, pp. 871-905.	
EXAMINER	DATE CONSIDERED 12/15/05		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.